Association between breast diseases and symptomatic uterine fibroids by using South Korean National Health Insurance database.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
05 10 2023
05 10 2023
Historique:
received:
19
01
2023
accepted:
24
09
2023
medline:
9
10
2023
pubmed:
6
10
2023
entrez:
5
10
2023
Statut:
epublish
Résumé
Both the uterus and breasts have sex hormone dependence, yet there are few studies on the association between breast disease and uterine fibroids (UFs). The purpose of this study was to investigate the incidence of benign breast disease (BBD), carcinoma in situ (CIS), and breast cancer (BC) in women treated for UFs compared to women who were not treated for UFs. This retrospective cohort study used national health insurance data from January 1st, 2011, to December 31st, 2020. We selected women between 20 and 50 years old who (1) were treated for UFs (UF group) or (2) visited medical institutions for personal health screening tests without UFs (control group). We analyzed independent variables such as age, socioeconomic status (SES), region, Charlson comorbidity index (CCI), delivery status, menopausal status, menopausal hormone therapy (MHT), endometriosis, hypertension (HTN), diabetes mellitus (DM), and dyslipidemia based on the first date of uterine myomectomy in the UF group and the first visiting date for health screening in the non-UF group. There were 190,583 and 439,940 participants in the UF and control groups, respectively. Compared with those of the control group, the RRs of BBD, CIS, and BC were increased in the UF group. The hazard ratios (HRs) of BBD, CIS, and BC in the UF group were 1.335 (95% confidence interval (CI) 1.299-1.372), 1.796 (95% CI 1.542-2.092), and 1.3 (95% CI 1.198-1.41), respectively. When we analyzed the risk of BC according to age at inclusion, UFs group had the increased risk of BCs in all age groups in comparison with control group. Women with low SES (HR 0.514, 95% CI 0.36-0.734) and living in rural areas (HR 0.889, 95% CI 0.822-0.962) had a lower risk of BC. Our study showed that women with UFs had a higher risk of BBD, CIS, and BC than those without UFs. This result suggests that women with UFs should be more conscious of BC than those without UFs. Therefore, doctors should consider recommending regular breast self-exams, mammography, or ultrasound for the early detection of BC in women with UFs.
Identifiants
pubmed: 37798304
doi: 10.1038/s41598-023-43443-w
pii: 10.1038/s41598-023-43443-w
pmc: PMC10555995
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
16772Informations de copyright
© 2023. Springer Nature Limited.
Références
Bulun, S. E. Uterine fibroids. N. Engl. J. Med. 369, 1344–1355 (2013).
pubmed: 24088094
Wright, J. D. et al. Nationwide trends in the performance of inpatient hysterectomy in the United States. Obstet. Gynecol. 122, 233–241 (2013).
pubmed: 23969789
pmcid: 3913114
Farquhar, C. M. & Steiner, C. A. Hysterectomy rates in the United States 1990–1997. Obstet. Gynecol. 99, 229–234 (2002).
pubmed: 11814502
Baird, D. D., Dunson, D. B., Hill, M. C., Cousins, D. & Schectman, J. M. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am. J. Obstet. Gynecol. 188, 100–107 (2003).
pubmed: 12548202
Marshall, L. M. et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet. Gynecol. 90, 967–973 (1997).
pubmed: 9397113
Reis, F. M., Bloise, E. & Ortiga-Carvalho, T. M. Hormones and pathogenesis of uterine fibroids. Best Pract. Res. Clin. Obstet. Gynaecol. 34, 13–24 (2016).
pubmed: 26725037
Sant’Anna, G. D. S. et al. Ovarian steroid hormones modulate the expression of progesterone receptors and histone acetylation patterns in uterine leiomyoma cells. Gynecol. Endocrinol. 33, 629–633 (2017).
pubmed: 28300476
Wise, L. A. et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: A prospective study. Am. J. Epidemiol. 159, 113–123 (2004).
pubmed: 14718211
Flake, G. P., Andersen, J. & Dixon, D. Etiology and pathogenesis of uterine leiomyomas: A review. Environ. Health Perspect. 111, 1037–1054 (2003).
pubmed: 12826476
pmcid: 1241553
Marsh, E. E. & Bulun, S. E. Steroid hormones and leiomyomas. Obstet. Gynecol. Clin. N. Am. 33, 59–67 (2006).
Barbarisi, A. et al. 17-beta estradiol elicits an autocrine leiomyoma cell proliferation: Evidence for a stimulation of protein kinase-dependent pathway. J. Cell. Physiol. 186, 414–424 (2001).
pubmed: 11169981
Ishikawa, H. et al. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology 151, 2433–2442 (2010).
pubmed: 20375184
pmcid: 2875812
Englund, K. et al. Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J. Clin. Endocrinol. Metab. 83, 4092–4096 (1998).
pubmed: 9814497
Rossouw, J. E. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288, 321–333 (2002).
pubmed: 12117397
Khan, S. A., Yee, K. A., Kaplan, C. & Siddiqui, J. F. Estrogen receptor alpha expression in normal human breast epithelium is consistent over time. Int. J. Cancer 102, 334–337 (2002).
pubmed: 12402301
Hughes, L. E., Mansel, R. E. & Webster, D. J. Aberrations of normal development and involution (ANDI): A new perspective on pathogenesis and nomenclature of benign breast disorders. Lancet 2, 1316–1319 (1987).
pubmed: 2890912
Petersen, O. W., Hoyer, P. E. & van Deurs, B. Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue. Cancer Res. 47, 5748–5751 (1987).
pubmed: 3664479
Hartmann, L. C. et al. Benign breast disease and the risk of breast cancer. N. Engl. J. Med. 353, 229–237 (2005).
pubmed: 16034008
Castells, X. et al. Breast cancer risk after diagnosis by screening mammography of nonproliferative or proliferative benign breast disease: A study from a population-based screening program. Breast Cancer Res. Treat. 149, 237–244 (2015).
pubmed: 25503778
Kim, L., Kim, J. A. & Kim, S. A guide for the utilization of health insurance review and assessment service national patient samples. Epidemiol. Health 36, e2014008 (2014).
pubmed: 25078381
pmcid: 4151963
Quan, H. et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am. J. Epidemiol. 173, 676–682 (2011).
pubmed: 21330339
Tseng, J. J., Chen, Y. H., Chiang, H. Y. & Lin, C. H. Increased risk of breast cancer in women with uterine myoma: A nationwide, population-based, case-control study. J. Gynecol. Oncol. 28, e35 (2017).
pubmed: 28382798
pmcid: 5391394
Shen, T. C. et al. Patients with uterine leiomyoma exhibit a high incidence but low mortality rate for breast cancer. Oncotarget 8, 33014–33023 (2017).
pubmed: 28380432
pmcid: 5464846
Mohan, A., Kumar, V., Brahmachari, S. & Pandya, B. A study on clinico-pathological profile of breast cancer patients and their correlation with uterine fibroids using hormone level and receptor status assessment. Breast Cancer (Auckl) 16, 11782234221090196 (2022).
pubmed: 35462755
Wise, L. A., Radin, R. G., Rosenberg, L., Adams-Campbell, L. & Palmer, J. R. History of uterine leiomyomata and incidence of breast cancer. Cancer Causes Control 26, 1487–1493 (2015).
pubmed: 26250515
pmcid: 4567934
Lethaby, A., Vollenhoven, B. & Sowter, M. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: A systematic review. BJOG 109, 1097–1108 (2002).
pubmed: 12387461
De Vivo, A. et al. Uterine myomas during pregnancy: A longitudinal sonographic study. Ultrasound Obstet. Gynecol. 37, 361–365 (2011).
pubmed: 20922776
Wu, X. et al. Investigating the shared genetic architecture of uterine leiomyoma and breast cancer: A genome-wide cross-trait analysis. Am. J. Hum. Genet. 109, 1272–1285 (2022).
pubmed: 35803233
pmcid: 9300879
Stewart, E. A., Cookson, C. L., Gandolfo, R. A. & Schulze-Rath, R. Epidemiology of uterine fibroids: A systematic review. BJOG 124, 1501–1512 (2017).
pubmed: 28296146
Van Voorhis, B. J., Romitti, P. A. & Jones, M. P. Family history as a risk factor for development of uterine leiomyomas. Results of a pilot study. J. Reprod. Med. 47, 663–669 (2002).
pubmed: 12216434
Baird, D. D., Dunson, D. B., Hill, M. C., Cousins, D. & Schectman, J. M. Association of physical activity with development of uterine leiomyoma. Am. J. Epidemiol. 165, 157–163 (2007).
pubmed: 17090618
Wise, L. A. et al. Intake of fruit, vegetables, and carotenoids in relation to risk of uterine leiomyomata. Am. J. Clin. Nutr. 94, 1620–1631 (2011).
pubmed: 22071705
pmcid: 3252555
Fu, Z. et al. Association between urinary phthalate metabolites and risk of breast cancer and uterine leiomyoma. Reprod. Toxicol. 74, 134–142 (2017).
pubmed: 28951174
Lukasiewicz, S. et al. Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers (Basel) 13, 4287 (2021).
pubmed: 34503097
Mohanty, S. S. & Mohanty, P. K. Obesity as potential breast cancer risk factor for postmenopausal women. Genes Dis. 8, 117–123 (2021).
pubmed: 33997158
Chlebowski, R. T. et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women’s health initiative randomized clinical trials. JAMA 324, 369–380 (2020).
pubmed: 32721007
pmcid: 7388026
Wielsoe, M., Kern, P. & Bonefeld-Jorgensen, E. C. Serum levels of environmental pollutants is a risk factor for breast cancer in Inuit: A case control study. Environ. Health 16, 56 (2017).
pubmed: 28610584
pmcid: 5470290
Wan, M. L. Y., Co, V. A. & El-Nezami, H. Endocrine disrupting chemicals and breast cancer: A systematic review of epidemiological studies. Crit. Rev. Food Sci. Nutr. 62, 1–27 (2021).
Morgan, M., Deoraj, A., Felty, Q. & Roy, D. Environmental estrogen-like endocrine disrupting chemicals and breast cancer. Mol. Cell. Endocrinol. 457, 89–102 (2017).
pubmed: 27717745
Braganza, M. Z. et al. Benign breast and gynecologic conditions, reproductive and hormonal factors, and risk of thyroid cancer. Cancer Prev. Res. (Phila) 7, 418–425 (2014).
pubmed: 24449056
Dyrstad, S. W., Yan, Y., Fowler, A. M. & Colditz, G. A. Breast cancer risk associated with benign breast disease: Systematic review and meta-analysis. Breast Cancer Res. Treat. 149, 569–575 (2015).
pubmed: 25636589
Katuwal, S., Tapanainen, J. & Pukkala, E. Multivariate analysis of independent roles of socioeconomic status, occupational physical activity, reproductive factors, and postmenopausal hormonal therapy in risk of breast cancer. Breast Cancer Res. Treat. 193, 495–505 (2022).
pubmed: 35366162
pmcid: 9090885
Klassen, A. C. & Smith, K. C. The enduring and evolving relationship between social class and breast cancer burden: A review of the literature. Cancer Epidemiol. 35, 217–234 (2011).
pubmed: 21470929
Farland, L. V. et al. A prospective study of endometriosis and risk of benign breast disease. Breast Cancer Res. Treat. 159, 545–552 (2016).
pubmed: 27604359
pmcid: 5310266
Ness, R. B. & Modugno, F. Endometriosis as a model for inflammation-hormone interactions in ovarian and breast cancers. Eur. J. Cancer 42, 691–703 (2006).
pubmed: 16531042
Melin, A., Sparen, P. & Bergqvist, A. The risk of cancer and the role of parity among women with endometriosis. Hum. Reprod. 22, 3021–3026 (2007).
pubmed: 17855408
Munksgaard, P. S. & Blaakaer, J. The association between endometriosis and gynecological cancers and breast cancer: A review of epidemiological data. Gynecol. Oncol. 123, 157–163 (2011).
pubmed: 21742370
Saavalainen, L. et al. A cohort study of 49,933 women with surgically verified endometriosis: Increased incidence of breast cancer below the age of 40. Acta Obstet. Gynecol. Scand. 98, 1113–1119 (2019).
pubmed: 30883685
Matta, J. L. et al. Women with endometriosis have a higher DNA repair capacity and diminished breast cancer risk. Mol. Cancer Biol. https://doi.org/10.9777/mcb.2013.10005 (2013).
doi: 10.9777/mcb.2013.10005
pubmed: 25473592
pmcid: 4248303
Kim, J. J., Kurita, T. & Bulun, S. E. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr. Rev. 34, 130–162 (2013).
pubmed: 23303565
pmcid: 3565104